The MOR103 drug substance was manufactured by DSM Biologics Company BV (Groningen, The Netherlands) and the drug product (sterile liquid formulation in glass vials) was manufactured by Rentschler Biotechnologie GmbH (Laupheim, Germany).
Anti-MOR103 antibodies
Serum samples were tested for anti-MOR103 IgG and IgM antibodies. One sample collected at week 10 from a subject treated with MOR103 1.0 mg/kg was confirmed positive for anti-MOR103 IgG antibodies. Because all later samples of the same subject tested negative, the immune response was recorded as a transient positive.
As there was no appropriate positive control available for the detection of anti-MOR103 IgM antibodies, study samples were only screened for potential positive samples.
Results from pre-dose (screening visit) values and placebo-treated patients were compared to results in MOR103-treated patients. At the screening visit, ELISA results for anti-MOR103 IgM antibodies were positive in 4 placebo subjects and 0, 3, and 4 subjects in the MOR103 0.3, 1.0, and 1.5 mg/kg groups, respectively. Post-treatment positive samples were found to be in the same range; 0 to 4 subjects were positive for potential anti-MOR103 IgM antibodies in each treatment group at weeks 10, 13, and 16.
Based on these results it was concluded that there were no obvious differences in the numbers of positive ELISA samples between placebo and MOR103 groups. Overall, there was no evidence that anti-MOR103 antibodies affected MOR103 serum concentrations or clinical outcomes. to the week 4 visit as specified in the study protocol. DAS28, Disease Activity Score-28 joints.
